Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer - Trial NCT06209099
Access comprehensive clinical trial information for NCT06209099 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University Cancer Hospital & Institute and is currently Recruiting. The study focuses on Rectal Cancer. Target enrollment is 67 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University Cancer Hospital & Institute
Timeline & Enrollment
N/A
Dec 05, 2023
Nov 01, 2025
Primary Outcome
Organ-preservation rate
Summary
The goal of this clinical trial is to test the safety and efficacy of local excision (LE) or
 non-operative management (NOM) in patients with MRI defined low-risk rectal cancer following
 neoadjuvant intensity modulated radiotherapy with concurrent capecitabine plus consolidation
 CapeOX. The main questions it aims to answer are:
 
 1. What is the organ-preservation rate (OPR) after in patients with MRI defined low-risk
 rectal cancer following neoadjuvant intensity modulated radiotherapy with concurrent
 capecitabine plus consolidation CapeOX?
 
 2. Is LE or NOM safe and effective in patients with MRI defined low-risk rectal cancer
 following neoadjuvant intensity modulated radiotherapy with concurrent capecitabine plus
 consolidation CapeOX? Participants will receive radical surgery, LE, or NOM based on the
 response of neoadjuvant intensity modulated radiotherapy with concurrent capecitabine
 plus consolidation CapeOX in patients with MRI defined low-risk rectal cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06209099
Non-Device Trial